Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
Synthekine has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in January 2023.
Synthekine's investors include RA Capital Management, Lilly Asia Ventures, Janus Henderson Investors, TCG Crossover, Canaan Partners.
Synthekine is headquartered in Menlo Park, United States.
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
Synthekine is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Synthekine — Funding & Investors." VCBacked, January 6, 2023, https://www.vcbacked.co/company/synthekine. Accessed September 29, 2026.
VCBacked. (2023). Synthekine — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/synthekine
{{cite web |title=Synthekine — Funding & Investors |url=https://www.vcbacked.co/company/synthekine |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated